{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:18:16Z","timestamp":1785467896295,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"LeukoTreat, FP7 Health 2009","award":["241622"],"award-info":[{"award-number":["241622"]}]},{"name":"UPenn Medicine, Million Dollar Bike ride","award":["MDBR-15-216-TSA"],"award-info":[{"award-number":["MDBR-15-216-TSA"]}]},{"name":"Friends of Department of Pediatrics of UKE"},{"name":"Myelin Project Germany e. V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Canavan disease (CD, MIM # 271900) is a rare and devastating leukodystrophy of early childhood. To identify clinical features that could serve as endpoints for treatment trials, the clinical course of CD was studied retrospectively and prospectively in 23 CD patients. Results were compared with data of CD patients reported in three prior large series. Kaplan Meier survival analysis including log rank test was performed for pooled data of 82 CD patients (study cohort and literature patients).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Onset of symptoms was between 0 and 6\u00a0months. Psychomotor development of patients was limited to abilities that are usually gained within the first year of life. Macrocephaly became apparent between 4 and 18\u00a0months of age. Seizure frequency was highest towards the end of the first decade. Ethnic background was more diverse than in studies previously reported. A CD severity score with assessment of 11 symptoms and abilities was developed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Early hallmarks of CD are severe psychomotor disability and macrocephaly that develop within the first 18\u00a0months of life. While rare in the first year of life, seizures increase in frequency over time in most patients. CD occurs more frequently outside Ashkenazi Jewish communities than previously reported. Concordance of phenotypes between siblings but not patients with identical <jats:italic>ASPA<\/jats:italic> mutations suggest the influence of yet unknown modifiers. A CD severity score may allow for assessment of CD disease severity both retrospectively and prospectively.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01659-3","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T09:03:04Z","timestamp":1621414984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The natural history of Canavan disease: 23 new cases and comparison with patients from literature"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-0938","authenticated-orcid":false,"given":"Annette","family":"Bley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfried","family":"Kohlsch\u00fctter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Guder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Bierhals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian S.","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"2","key":"1659_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ajmg.1320290234","volume":"29","author":"R Matalon","year":"1988","unstructured":"Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet. 1988;29(2):463\u201371.","journal-title":"Am J Med Genet"},{"issue":"3","key":"1659_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1385\/JMN:21:3:185","volume":"21","author":"MH Baslow","year":"2003","unstructured":"Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci. 2003;21(3):185\u201390.","journal-title":"J Mol Neurosci"},{"issue":"122","key":"1659_CR3","first-page":"920","volume":"23","author":"J Campistol","year":"1995","unstructured":"Campistol J, Capdevila A, Moreno A. Neuroimaging in Canavan disease. Rev Neurol. 1995;23(122):920\u20131 (PMID: 7497260).","journal-title":"Rev Neurol"},{"issue":"1","key":"1659_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/gte.1997.1.21","volume":"1","author":"R Matalon","year":"1997","unstructured":"Matalon R. Canavan disease: diagnosis and molecular analysis. Genet Test. 1997;1(1):21\u20135. https:\/\/doi.org\/10.1089\/gte.1997.1.21.","journal-title":"Genet Test"},{"issue":"2","key":"1659_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0022-510X(76)90101-5","volume":"28","author":"P Mirimanoff","year":"1976","unstructured":"Mirimanoff P. Hereditary spongiform dystrophy in young children (Canavan: van Bogaert-Bertrand). J Neurol Sci. 1976;28(2):159\u201385 (PMID: 1271080).","journal-title":"J Neurol Sci"},{"issue":"2","key":"1659_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-2008-1071269","volume":"20","author":"B Echenne","year":"1989","unstructured":"Echenne B, Divry P, Vianey-Liaud C. Spongy degeneration of the neuraxis (Canavan-van Bogaert disease) and N-acetylaspartic aciduria. Neuropediatrics. 1989;20(2):79\u201381. https:\/\/doi.org\/10.1055\/s-2008-1071269.","journal-title":"Neuropediatrics"},{"issue":"3","key":"1659_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11064-018-2693-6","volume":"45","author":"D Pleasure","year":"2020","unstructured":"Pleasure D, Guo F, Chechneva O, Bannerman P, McDonough J, Burns T, Wang Y, Hull V. Pathophysiology and treatment of canavan disease. Neurochem Res. 2020;45(3):561\u20135. https:\/\/doi.org\/10.1007\/s11064-018-2693-6.","journal-title":"Neurochem Res"},{"key":"1659_CR8","unstructured":"Frankenburg WF, Dodds J, et al, Denver Developmental Screening Test II DENVER II, Training Manual. 5th ed. Denver, Colorado\/Denver developmental material Inc. 1992;pp. 4."},{"issue":"9","key":"1659_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.clinbiochem.2014.05.039","volume":"47","author":"KP Kohse","year":"2014","unstructured":"Kohse KP. KiGGS - the German survey on children\u2019s health as data base for reference intervals and beyond. Clin Biochem. 2014;47(9):742\u20133. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.05.039.","journal-title":"Clin Biochem"},{"issue":"3","key":"1659_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0887-8994(97)00185-9","volume":"18","author":"EC Traeger","year":"1998","unstructured":"Traeger EC, Rapin I. The clinical course of Canavan disease. Pediatr Neurol. 1998;18(3):207\u201312 (PMID: 9568915).","journal-title":"Pediatr Neurol"},{"issue":"2","key":"1659_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ajmg.1320350224","volume":"35","author":"PT Ozand","year":"1990","unstructured":"Ozand PT, Gascon GG, Dhalla M. Aspartoacylase deficiency and Canavan disease in Saudi Arabia. Am J Med Genet. 1990;35(2):266\u20138. https:\/\/doi.org\/10.1002\/ajmg.1320350224.","journal-title":"Am J Med Genet"},{"key":"1659_CR12","unstructured":"Shaag A, Anikster Y, Christensen E, Glustein JZ, Fois A, Michelakakis H, et al. The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet. 1995;57(3):572\u201380 (PMCID: 7668285)."},{"issue":"43","key":"1659_CR13","doi-asserted-by":"publisher","first-page":"14501","DOI":"10.1523\/JNEUROSCI.1056-15","volume":"35","author":"H Maier","year":"2015","unstructured":"Maier H, Wang-Eckhardt L, Hartmann D, Gieselmann V, Eckhardt M. N-Acetylaspartate synthase deficiency corrects the myelin phenotype in a canavan disease mouse model but does not affect survival time. J Neurosci. 2015;35(43):14501\u201316. https:\/\/doi.org\/10.1523\/JNEUROSCI.1056-15.","journal-title":"J Neurosci"},{"issue":"4","key":"1659_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.biochi.2012.10.023","volume":"95","author":"MH Baslow","year":"2013","unstructured":"Baslow MH, Guilfoyle DN. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie. 2013;95(4):946\u201356. https:\/\/doi.org\/10.1016\/j.biochi.2012.10.023.","journal-title":"Biochimie"},{"issue":"2","key":"1659_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11011-010-9202-1","volume":"25","author":"CD Pederzolli","year":"2010","unstructured":"Pederzolli CD, Mescka CP, Magnusson AS, Deckmann KB, de Souza SE, Sgaravatti AM, et al. N-acetylaspartic acid impairs enzymatic antioxidant defenses and enhances hydrogen peroxide concentration in rat brain. Metab Brain Dis. 2010;25(2):251\u20139. https:\/\/doi.org\/10.1007\/s11011-010-9202-1.","journal-title":"Metab Brain Dis"},{"issue":"6","key":"1659_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/00207454.2011.558225","volume":"121","author":"S Surendran","year":"2011","unstructured":"Surendran S, Bhatnagar M. Upregulation of N-acetylaspartic acid induces oxidative stress to contribute in disease pathophysiology. Int J Neurosci. 2011;121(6):305\u20139. https:\/\/doi.org\/10.3109\/00207454.2011.558225.","journal-title":"Int J Neurosci"},{"key":"1659_CR17","unstructured":"Lyon G; Kolodny E H; Pastores G M, Neurology of hereditary metabolic diseases of children, New York: McGraw-Hill, 2006, x, 542 p. 3rd ed."},{"issue":"5","key":"1659_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/humu.23181","volume":"38","author":"MI Mendes","year":"2017","unstructured":"Mendes MI, Smith DE, Pop A, Lennertz P, Fernandez Ojeda MR, Kanhai WA, et al. Clinically distinct phenotypes of canavan disease correlate with residual aspartoacylase enzyme activity. Hum Mutat. 2017;38(5):524\u201331. https:\/\/doi.org\/10.1002\/humu.23181.","journal-title":"Hum Mutat"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01659-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T10:14:09Z","timestamp":1635416049000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01659-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01659-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Medical Association of Hamburg, Germany, in 2011 (PV3782).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"For all participants informed consent for participation of this study and publication of the results was given.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have indicated they have no financial relationships relevant to this article to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}